News

Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”

Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension…

2 years ago

Chromocell Issues Letter to Stockholders from Chief Executive Officer

FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer…

2 years ago

Allogene Therapeutics Announces Q2 Investor Conference Participation

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering…

2 years ago

Autonomix Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation

Preclinical study demonstrates potential of Autonomix technology to make renal denervation safer and more effective Ongoing advancement of sensing and…

2 years ago

Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing

The new Gen-3 HALO™ Clarity 15 milliamp (mA) The new Gen-3 HALO™ Clarity 15 milliamp (mA) The new Gen-3 HALO™…

2 years ago

Tome Biosciences Announces US Patent Issued for Integrase-Mediated Programmable Genomic Integration

WATERTOWN, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announces the…

2 years ago

Clearmind Medicine CEO Issues Letter to Shareholders

Vancouver, Canada, April 09, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq:CMND), (FSE: CWY0) (“Clearmind” or the “company”), a clinical-stage…

2 years ago

Mainz Biomed Reports Full Year 2023 Financial Results

ColoAlert® Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of…

2 years ago